Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab to Monitor Immune Responses in Metastatic Triple Negative Breast Cancer

NCT05742269 is registered in ClinicalTrials.gov with Karolinska University Hospital as lead sponsor.

NCT NCT05742269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05742269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab to Monitor Immune Responses in Metastatic Triple Negative Breast Cancer
Lead sponsor
Karolinska University Hospital
Phase
Observational
Overall status
Terminated
Start date
July 1, 2023
Completion date
March 11, 2026
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic triple-negative breast carcinoma